Geriatric Assessment and Intervention for Older Patients With Frailty in the Emergency Department (GAOPS)

August 4, 2021 updated by: Janne Alakare, Helsinki University Central Hospital

Geriatric Assessment and Intervention for Older Patients With Frailty in the Emergency Department. Randomized Controlled Trial

Comprehensive Geriatric Assessment (CGA) is an established approach for better detection of frailty-related problems and includes individualized treatment plan with multi-discipline supportive and treating measures for the older frailty patients. However, there is limited evidence of feasibility and efficacy of the CGA when provided in the emergency department setting.

In the GAOPS-study the efficacy of the CGA in emergency department setting will be studied by randomized controlled study protocol. We aim to study if the CGA provided in the ED is feasible, safe and efficient method when added with standard emergency care for older frail patients.

Study Overview

Study Type

Interventional

Enrollment (Actual)

432

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Uusimaa
      • Espoo, Uusimaa, Finland, 02740
        • Helsinki University Hospital, Jorvi ED

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

73 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age of minimum 75 years
  • "Clinical Frailty Scale" minimum 4 estimated at the arrival to the ED by nurse

Exclusion Criteria:

  • Non-resident of the counties (City of Espoo, Kirkkonummi, Kauniainen) of the hospital district.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard Emergency Care + CGA
Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
Comprehensive Geriatric Assessment
No Intervention: Standard Emergency Care
Standard Care is provided for the acute condition as usual by the ED personnel.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulated Length of Stay
Time Frame: Day 365
Cumulated stay (days) in hospital wards (university hospital and community hospital) including all admissions during the follow-up.
Day 365

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Admissions
Time Frame: Day 30, Day 365
Number of admissions to the hospital wards (university hospital and community hospital) during the follow-up.
Day 30, Day 365
Admission rate
Time Frame: Day 0
Proportion of admitted patients (university hospital or community hospital ward) from the index ED-visits.
Day 0
Readmissions in the ED
Time Frame: Hour 72, Day 30, Day 365
Re-visits to the ED after the index-visit.
Hour 72, Day 30, Day 365
Living at home
Time Frame: Day 365
Proportion of the patients living at home.
Day 365
Quality of Life
Time Frame: Day 0, Day 365
Change of the quality of life during one year follow-up using the standardized questionnaire EuroQol EQ-5D-5L. Measured value is the index value defined by the EuroQol group.
Day 0, Day 365

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length-of-Stay in the ED
Time Frame: Day 0
Length-of-Stay (h) of the index-visit in the ED
Day 0
Length-of-Stay in the ward
Time Frame: Day 365
Length-of-Stay (d) in the hospital ward of admitted patients from the index-visit in the ED
Day 365
Mortality
Time Frame: Day 365
Mortality during the one-year follow-up.
Day 365
Falls
Time Frame: Day 365
Number of falls which result in new ED visit during the one-year follow-up
Day 365

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Veli-Pekka Harjola, Department of Emergency Medicine and Services, Helsinki University Hospital
  • Principal Investigator: Janne Alakare, MD, Department of Emergency Medicine and Services, Helsinki University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 11, 2018

Primary Completion (Actual)

June 7, 2020

Study Completion (Actual)

July 2, 2021

Study Registration Dates

First Submitted

November 18, 2018

First Submitted That Met QC Criteria

November 21, 2018

First Posted (Actual)

November 23, 2018

Study Record Updates

Last Update Posted (Actual)

August 11, 2021

Last Update Submitted That Met QC Criteria

August 4, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • TYH2018304
  • HUS1171/2018 (Other Identifier: Helsinki University Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on CGA

3
Subscribe